Simon Alesi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simon Alesi has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Aya Mousa
Monash University
11 shared publications Chau Thien Tay
Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University , Clayton, Victoria 3168 , Australia
6 shared publications- Helena Jane Teede
Monash Centre for Health Research and Implementation, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
5 shared publications Helena Teede
5 shared publications- Daniela Romualdi
Department of Woman and Child Health and Public Health, Woman Health Area, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
4 shared publications Eveline Jona
Monash Centre for Health Research and Implementation (MCHRI), Monash University , Melbourne, VIC
4 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (4)
Metabolic and hormonal biomarkers in pregnancies with polyendocrine metabolic ovarian syndrome (formerly polycystic ovary syndrome): a nested prospective cohort study with longitudinal sub-analysis
STUDY QUESTION: Do metabolic and hormonal biomarker profiles in early pregnancy and their longitudinal variations across gestation differ among women at high risk of gestational diabetes mellitus (GDM) with and without polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome [PCOS]), and are they associated with maternal and neonatal complications? SUMMARY ANSWER: Among pregnant women at high risk of GDM, PMOS was associated with persistently elevated free androgen index (FAI) throughout pregnancy, whereas no interaction between elevated FAI and PMOS status on maternal and neonatal complications was identified. WHAT IS KNOWN ALREADY: Insulin resistance and hyperandrogenism are important pathophysiologic features of PMOS and are also part of the physiological changes during normal pregnancy. Pregnancies with PMOS have been associated with a higher risk of maternal and neonatal complications than those without PMOS. STUDY DESIGN, SIZE, DURATION: Nested prospective cohort study with longitudinal sub-analysis using pooled data from two international multicentre clinical trials (TOBOGM study and B2B&Me trial). A total of 151 pregnancies at high risk for GDM were included from January 2018 to December 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: At baseline (before 24 weeks’ gestation), 151 pregnancies at high risk for GDM were included (65 PMOS and 86 non-PMOS). Longitudinal sub-analysis included 75 pregnancies (15 PMOS and 60 non-PMOS). Metabolic biomarkers (fasting plasma glucose [FPG], insulin, C-peptide) and hormonal biomarkers (testosterone, dihydrotestosterone [DHT], androstenedione [A4], sex hormone-binding globulin [SHBG], and anti-Mullerian hormone [AMH]) were measured to derive indices of insulin resistance (homeostatic model assessment for insulin resistance [HOMA-IR], quantitative insulin sensitivity check index [QUICKI], fasting glucose to insulin ratio [FGIR]) and FAI. These were assessed cross-sectionally and in exploratory longitudinal sub-analyses of a subset of participants across gestation using linear mixed-effects models. Interaction analyses explored whether biomarkers modified associations between PMOS and adverse maternal or neonatal outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: PMOS was associated with higher pre-pregnancy and baseline BMI and greater insulin resistance (elevated fasting insulin, HOMA-IR, and FGIR, and lower QUICKI). Androgen profiles differed significantly, with PMOS associated with higher DHT (167.8 vs 121.2 pg/ml, P = 0.003) and FAI (0.9 vs 0.5, P < 0.001) and lower SHBG (159.1 vs 215.3 nmol/l, P = 0.012), compared with non-PMOS controls. FAI in early pregnancy was independently associated with PMOS (geometric mean ratio 1.9, P = 0.003) and, in exploratory longitudinal sub-analyses, remained elevated throughout pregnancy in women with PMOS. Maternal and neonatal complications did not differ between groups, and no interactions between FAI, PMOS status, and composite adverse outcomes were identified. LIMITATIONS, REASONS FOR CAUTION: The selective inclusion of a high-risk cohort limited generalization. Minimized or neutralized differences in maternal and neonatal outcomes between groups may be observed due to timely screening, diagnosis, and intervention within the parent RCT protocols. Since this was a sub-study, no formal a priori power calculation was conducted. Consequently, the study may possess limited statistical power to identify smaller effect sizes, longitudinal changes, and interaction effects; therefore, the findings should be interpreted with caution. WIDER IMPLICATIONS OF THE FINDINGS: Persistently elevated FAI throughout pregnancy, potentially reflecting an inadequate protective SHBG response to pregnancy-induced androgen excess. Whether elevated FAI contributes to adverse pregnancy outcomes in PMOS warrants further longitudinal evaluation. FUNDING: TOBOGM was funded by the National Health and Medical Research Council (NMHRC; grants 1104231 and 2009326), the Region Örebro Research Committee (grants Dnr OLL-970566 and OLL-942177), Medical Scientific Fund of the Mayor of Vienna (project 15205), the South-Western Sydney Local Health District Academic Unit (grant 2016), and a Western Sydney University Ainsworth Trust Grant (2019). B2B&Me was funded by the European Union Commission Horizon 2020 grant entitled ‘Implementation Action to Prevent Diabetes from Bump 2 Baby (IMPACT DIABETES B2B&Me)’ under grant agreement 847984, with collaborative NHMRC, Australia co-funding under grant number APP1194234. The project was sponsored by the University College Dublin. S.A., A.C.H.N., and T.M. are supported by Graduate Research Scholarships provided by Monash University. K.R. is supported by a scholarship from the NHMRC. S.J.E., H.T., and A.M. are supported by fellowships from the NHMRC. DISCLOSURES: The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBERS: ACTRN12616000924459 and ACTRN12620001240932.
- 17 September 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (4)
Open AccessMetabolic and hormonal biomarkers in pregnancies with polyendocrine metabolic ovarian syndrome (formerly polycystic ovary syndrome): a nested prospective cohort study with longitudinal sub-analysis
STUDY QUESTION: Do metabolic and hormonal biomarker profiles in early pregnancy and their longitudinal variations across gestation differ among women at high risk of gestational diabetes mellitus (GDM) with and without polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome [PCOS]), and are they associated with maternal and neonatal complications? SUMMARY ANSWER: Among pregnant women at high risk of GDM, PMOS was associated with persistently elevated free androgen index (FAI) throughout pregnancy, whereas no interaction between elevated FAI and PMOS status on maternal and neonatal complications was identified. WHAT IS KNOWN ALREADY: Insulin resistance and hyperandrogenism are important pathophysiologic features of PMOS and are also part of the physiological changes during normal pregnancy. Pregnancies with PMOS have been associated with a higher risk of maternal and neonatal complications than those without PMOS. STUDY DESIGN, SIZE, DURATION: Nested prospective cohort study with longitudinal sub-analysis using pooled data from two international multicentre clinical trials (TOBOGM study and B2B&Me trial). A total of 151 pregnancies at high risk for GDM were included from January 2018 to December 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: At baseline (before 24 weeks’ gestation), 151 pregnancies at high risk for GDM were included (65 PMOS and 86 non-PMOS). Longitudinal sub-analysis included 75 pregnancies (15 PMOS and 60 non-PMOS). Metabolic biomarkers (fasting plasma glucose [FPG], insulin, C-peptide) and hormonal biomarkers (testosterone, dihydrotestosterone [DHT], androstenedione [A4], sex hormone-binding globulin [SHBG], and anti-Mullerian hormone [AMH]) were measured to derive indices of insulin resistance (homeostatic model assessment for insulin resistance [HOMA-IR], quantitative insulin sensitivity check index [QUICKI], fasting glucose to insulin ratio [FGIR]) and FAI. These were assessed cross-sectionally and in exploratory longitudinal sub-analyses of a subset of participants across gestation using linear mixed-effects models. Interaction analyses explored whether biomarkers modified associations between PMOS and adverse maternal or neonatal outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: PMOS was associated with higher pre-pregnancy and baseline BMI and greater insulin resistance (elevated fasting insulin, HOMA-IR, and FGIR, and lower QUICKI). Androgen profiles differed significantly, with PMOS associated with higher DHT (167.8 vs 121.2 pg/ml, P = 0.003) and FAI (0.9 vs 0.5, P < 0.001) and lower SHBG (159.1 vs 215.3 nmol/l, P = 0.012), compared with non-PMOS controls. FAI in early pregnancy was independently associated with PMOS (geometric mean ratio 1.9, P = 0.003) and, in exploratory longitudinal sub-analyses, remained elevated throughout pregnancy in women with PMOS. Maternal and neonatal complications did not differ between groups, and no interactions between FAI, PMOS status, and composite adverse outcomes were identified. LIMITATIONS, REASONS FOR CAUTION: The selective inclusion of a high-risk cohort limited generalization. Minimized or neutralized differences in maternal and neonatal outcomes between groups may be observed due to timely screening, diagnosis, and intervention within the parent RCT protocols. Since this was a sub-study, no formal a priori power calculation was conducted. Consequently, the study may possess limited statistical power to identify smaller effect sizes, longitudinal changes, and interaction effects; therefore, the findings should be interpreted with caution. WIDER IMPLICATIONS OF THE FINDINGS: Persistently elevated FAI throughout pregnancy, potentially reflecting an inadequate protective SHBG response to pregnancy-induced androgen excess. Whether elevated FAI contributes to adverse pregnancy outcomes in PMOS warrants further longitudinal evaluation. FUNDING: TOBOGM was funded by the National Health and Medical Research Council (NMHRC; grants 1104231 and 2009326), the Region Örebro Research Committee (grants Dnr OLL-970566 and OLL-942177), Medical Scientific Fund of the Mayor of Vienna (project 15205), the South-Western Sydney Local Health District Academic Unit (grant 2016), and a Western Sydney University Ainsworth Trust Grant (2019). B2B&Me was funded by the European Union Commission Horizon 2020 grant entitled ‘Implementation Action to Prevent Diabetes from Bump 2 Baby (IMPACT DIABETES B2B&Me)’ under grant agreement 847984, with collaborative NHMRC, Australia co-funding under grant number APP1194234. The project was sponsored by the University College Dublin. S.A., A.C.H.N., and T.M. are supported by Graduate Research Scholarships provided by Monash University. K.R. is supported by a scholarship from the NHMRC. S.J.E., H.T., and A.M. are supported by fellowships from the NHMRC. DISCLOSURES: The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBERS: ACTRN12616000924459 and ACTRN12620001240932.
- Open Access
- 19 May 2026
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (8) , 1490-1501
Prolactin in high‐metabolic risk pregnancies: Associations with maternal obesity and metabolic health
Introduction: Low prolactin levels during pregnancy have been linked to adverse maternal metabolic health. We examined pregnancy prolactin levels in relation to maternal metabolic characteristics within an ethnically diverse cohort at high metabolic risk. Material and Methods: In this observational cohort study, pregnant women ( n = 130) with metabolic risk factors were characterized in early pregnancy, with sampling of serum prolactin and metabolic parameters. Fifty‐four women with gestational diabetes consented to serial profiling across pregnancy. Univariable and multivariable simple and mixed‐effects regression models examined relationships between prolactin and maternal variables. Results: Women with obesity (BMI ≥30 kg/m 2 ) had lower early pregnancy prolactin levels than women without obesity (35.1 vs 44.3 μg/L, p = 0.03). Lower prolactin in early pregnancy was associated with higher parity and higher early pregnancy BMI, fasting insulin, insulin resistance, and diastolic blood pressure, but only relationships with parity and BMI persisted after adjustment for covariates. In the serially sampled cohort, lower prolactin levels across pregnancy were independently associated with higher pre‐pregnancy maternal BMI (adjusted β = −3.25, p = 0.04). Lower absolute prolactin increment from early to late pregnancy was independently associated with higher pre‐pregnancy and early pregnancy maternal BMI ( p = 0.046 and p = 0.04, respectively). Conclusions: Maternal metabolic status, particularly higher BMI before and during early pregnancy, was associated with lower prolactin levels in early pregnancy and across gestation, and a smaller prolactin increase over pregnancy. Lower prolactin levels may reflect underlying metabolic health and may be relevant to the suboptimal lactation outcomes observed in women with obesity and metabolic disease.
- 19 May 2026
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (8) , 1490-1501
Open AccessProlactin in high‐metabolic risk pregnancies: Associations with maternal obesity and metabolic health
Introduction: Low prolactin levels during pregnancy have been linked to adverse maternal metabolic health. We examined pregnancy prolactin levels in relation to maternal metabolic characteristics within an ethnically diverse cohort at high metabolic risk. Material and Methods: In this observational cohort study, pregnant women ( n = 130) with metabolic risk factors were characterized in early pregnancy, with sampling of serum prolactin and metabolic parameters. Fifty‐four women with gestational diabetes consented to serial profiling across pregnancy. Univariable and multivariable simple and mixed‐effects regression models examined relationships between prolactin and maternal variables. Results: Women with obesity (BMI ≥30 kg/m 2 ) had lower early pregnancy prolactin levels than women without obesity (35.1 vs 44.3 μg/L, p = 0.03). Lower prolactin in early pregnancy was associated with higher parity and higher early pregnancy BMI, fasting insulin, insulin resistance, and diastolic blood pressure, but only relationships with parity and BMI persisted after adjustment for covariates. In the serially sampled cohort, lower prolactin levels across pregnancy were independently associated with higher pre‐pregnancy maternal BMI (adjusted β = −3.25, p = 0.04). Lower absolute prolactin increment from early to late pregnancy was independently associated with higher pre‐pregnancy and early pregnancy maternal BMI ( p = 0.046 and p = 0.04, respectively). Conclusions: Maternal metabolic status, particularly higher BMI before and during early pregnancy, was associated with lower prolactin levels in early pregnancy and across gestation, and a smaller prolactin increase over pregnancy. Lower prolactin levels may reflect underlying metabolic health and may be relevant to the suboptimal lactation outcomes observed in women with obesity and metabolic disease.
- Open Access
- 9 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , e1961-e1972
Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome
Objective: To profile biomarkers of inflammation and metabolic regulation in early pregnancy among women with and without polycystic ovary syndrome (PCOS), and to assess whether these biomarkers influence the relationship between PCOS and adverse maternal or neonatal outcomes. Design: Cross-sectional study with interaction analyses using pooled baseline data from 2 international multicenter clinical trials. Subjects: One hundred and fifty-one pregnant women (at <24 weeks’ gestation) at risk of gestational diabetes mellitus, including 65 with PCOS and 86 without PCOS. Main outcome measures: Early pregnancy markers of inflammation and metabolic regulation were assessed, including C-reactive protein, tumor necrosis factor-α, interleukins, monocyte chemoattractant protein-1 (MCP1), fatty acid binding protein-4 (FABP4), growth differentiation factor-15, and adipokines (total adiponectin, leptin, resistin, chemerin, vaspin, and cathepsin-S). Biomarkers differing by PCOS status were further examined for interaction effects on maternal and neonatal outcomes. Results: Monocyte chemoattractant protein-1 concentrations were 15% higher in women with PCOS compared with those without (geometric mean ratio [GMR]: 1.15; 95% CI: 1.01, 1.31; P & .04), but this association was attenuated after adjustment for maternal age and body mass index (BMI). Early pregnancy FABP4 concentrations were 32% higher in women with PCOS compared with those without (GMR: 1.32; 95% CI: 1.04, 1.68; P & .02), and this association remained significant after adjustment for maternal age (GMR: 1.34; 95% CI: 1.05-1.71; P & .02), but was attenuated after adjustment for BMI. No other biomarkers differed by PCOS status, and MCP1 or FABP4 showed no interactions with maternal or neonatal outcomes. Conclusion: Monocyte chemoattractant protein-1 and FABP4 concentrations were elevated in early pregnancy among women with PCOS, largely reflecting maternal adiposity. These markers did not modify associations between PCOS and pregnancy outcomes. Larger longitudinal studies are needed to clarify underlying inflammatory and metabolic pathways.
- 9 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , e1961-e1972
Open AccessEarly pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome
Objective: To profile biomarkers of inflammation and metabolic regulation in early pregnancy among women with and without polycystic ovary syndrome (PCOS), and to assess whether these biomarkers influence the relationship between PCOS and adverse maternal or neonatal outcomes. Design: Cross-sectional study with interaction analyses using pooled baseline data from 2 international multicenter clinical trials. Subjects: One hundred and fifty-one pregnant women (at <24 weeks’ gestation) at risk of gestational diabetes mellitus, including 65 with PCOS and 86 without PCOS. Main outcome measures: Early pregnancy markers of inflammation and metabolic regulation were assessed, including C-reactive protein, tumor necrosis factor-α, interleukins, monocyte chemoattractant protein-1 (MCP1), fatty acid binding protein-4 (FABP4), growth differentiation factor-15, and adipokines (total adiponectin, leptin, resistin, chemerin, vaspin, and cathepsin-S). Biomarkers differing by PCOS status were further examined for interaction effects on maternal and neonatal outcomes. Results: Monocyte chemoattractant protein-1 concentrations were 15% higher in women with PCOS compared with those without (geometric mean ratio [GMR]: 1.15; 95% CI: 1.01, 1.31; P & .04), but this association was attenuated after adjustment for maternal age and body mass index (BMI). Early pregnancy FABP4 concentrations were 32% higher in women with PCOS compared with those without (GMR: 1.32; 95% CI: 1.04, 1.68; P & .02), and this association remained significant after adjustment for maternal age (GMR: 1.34; 95% CI: 1.05-1.71; P & .02), but was attenuated after adjustment for BMI. No other biomarkers differed by PCOS status, and MCP1 or FABP4 showed no interactions with maternal or neonatal outcomes. Conclusion: Monocyte chemoattractant protein-1 and FABP4 concentrations were elevated in early pregnancy among women with PCOS, largely reflecting maternal adiposity. These markers did not modify associations between PCOS and pregnancy outcomes. Larger longitudinal studies are needed to clarify underlying inflammatory and metabolic pathways.
- Open Access
- 22 August 2025
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 32 (1) , 105-127
Preconception lifestyle interventions for women—a systematic review and meta-analysis of intervention characteristics and behaviour change techniques
BACKGROUND: The time before conception is an important opportunity to improve maternal lifestyle, and hence improve fertility and health. However, the components of effective preconception lifestyle interventions are unclear. OBJECTIVE AND RATIONALE: This review aimed to assess the association of intervention characteristics and behaviour change techniques with the effect of lifestyle interventions on fertility, obstetric, foetal, anthropometric, and metabolic outcomes in women planning a pregnancy. Understanding the optimal components of preconception lifestyle interventions is essential to improve success of future interventions. SEARCH METHODS: We searched Ovid MEDLINE, PsycINFO, Embase, Emcare, Scopus, Cochrane Central Register of Controlled Trials, and CINAHL (6 December 2024). We included randomized controlled trials on women planning a pregnancy which assessed the effect of lifestyle intervention compared to standard minimal care or no intervention on fertility, obstetric, foetal, anthropometric, and metabolic outcomes. We performed random-effects meta-analysis with subgroup analysis based on participant characteristics, intervention characteristics (using the Template for Intervention Description and Replication (TIDieR) framework), and behaviour change techniques (using the Behaviour Change Taxonomy v1). We assessed trustworthiness (using the Trustworthiness in Randomised Controlled Trials (TRACT) checklist), risk of bias (using the Cochrane Risk of Bias 2.0 tool), and certainty of the evidence (using the GRADE approach). OUTCOMES: Following eligibility screening and trustworthiness assessments, we included 24 studies (n = 7795 women), of which the majority were conducted in high-income countries (79%) and studied women with infertility (67%). Risk of bias was low for seven studies, some concerns for 15 studies and high for two studies. Overall, there was no difference in clinical pregnancy (odds ratio [95% CI]: 1.06 [0.84, 1.35], I2 = 24.22%) or live birth (odds ratio [95% CI]: 1.17 [0.82, 1.67], I2 = 48.73%) with lifestyle intervention. Odds of clinical pregnancy were higher for interventions delivered over ≥10 sessions (2.17 [1.21, 3.86] vs 0.88 [0.72, 1.07], P = 0.004 for subgroup differences) and with the behaviour change technique Adding objects to the environment (e.g. provision of intervention-compliant food and/or exercise equipment) (3.51 [1.70, 7.23] vs 0.90 [0.75, 1.08], P < 0.001 for subgroup differences). Lifestyle interventions reduced weight (mean difference [95% CI]: −3.87 kg [−5.76, −1.97], I2 = 95.03%) and fasting blood glucose (mean difference [95% CI]: −0.15 mM [−0.25, −0.04], I2 = 0%). Greater weight loss was observed for interventions with a weight loss aim (−4.19 kg [−6.30, −1.92] vs −0.81 kg [−1.48, −0.14], P = 0.003 for subgroup differences). Greater weight loss was observed for interventions delivered solely via face-to-face (−6.02 kg [−8.96, −3.07]) compared to those delivered via a combination of face-to-face and technology (−2.21 kg [−3.62, −0.81], P = 0.02 for subgroup differences). WIDER IMPLICATIONS: Effectiveness of preconception lifestyle interventions aiming to enhance fertility may be improved by a structured, intensive approach. Preconception lifestyle interventions reduce weight, particularly face-to-face interventions with a weight loss aim. However, these findings based on subgroup analyses should be interpreted with caution and warrant further investigation due to the exploratory nature of the analysis, limited number of studies included, and potential aggregation bias of study-level subgroup effects. Selection of intervention characteristics for future preconception lifestyle interventions should consider patient preferences and practical considerations. REGISTRATION: This review was prospectively registered in the Prospective Register of Systematic Reviews (PROSPERO) (CRD42022333066).
- 22 August 2025
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 32 (1) , 105-127
Open AccessPreconception lifestyle interventions for women—a systematic review and meta-analysis of intervention characteristics and behaviour change techniques
BACKGROUND: The time before conception is an important opportunity to improve maternal lifestyle, and hence improve fertility and health. However, the components of effective preconception lifestyle interventions are unclear. OBJECTIVE AND RATIONALE: This review aimed to assess the association of intervention characteristics and behaviour change techniques with the effect of lifestyle interventions on fertility, obstetric, foetal, anthropometric, and metabolic outcomes in women planning a pregnancy. Understanding the optimal components of preconception lifestyle interventions is essential to improve success of future interventions. SEARCH METHODS: We searched Ovid MEDLINE, PsycINFO, Embase, Emcare, Scopus, Cochrane Central Register of Controlled Trials, and CINAHL (6 December 2024). We included randomized controlled trials on women planning a pregnancy which assessed the effect of lifestyle intervention compared to standard minimal care or no intervention on fertility, obstetric, foetal, anthropometric, and metabolic outcomes. We performed random-effects meta-analysis with subgroup analysis based on participant characteristics, intervention characteristics (using the Template for Intervention Description and Replication (TIDieR) framework), and behaviour change techniques (using the Behaviour Change Taxonomy v1). We assessed trustworthiness (using the Trustworthiness in Randomised Controlled Trials (TRACT) checklist), risk of bias (using the Cochrane Risk of Bias 2.0 tool), and certainty of the evidence (using the GRADE approach). OUTCOMES: Following eligibility screening and trustworthiness assessments, we included 24 studies (n = 7795 women), of which the majority were conducted in high-income countries (79%) and studied women with infertility (67%). Risk of bias was low for seven studies, some concerns for 15 studies and high for two studies. Overall, there was no difference in clinical pregnancy (odds ratio [95% CI]: 1.06 [0.84, 1.35], I2 = 24.22%) or live birth (odds ratio [95% CI]: 1.17 [0.82, 1.67], I2 = 48.73%) with lifestyle intervention. Odds of clinical pregnancy were higher for interventions delivered over ≥10 sessions (2.17 [1.21, 3.86] vs 0.88 [0.72, 1.07], P = 0.004 for subgroup differences) and with the behaviour change technique Adding objects to the environment (e.g. provision of intervention-compliant food and/or exercise equipment) (3.51 [1.70, 7.23] vs 0.90 [0.75, 1.08], P < 0.001 for subgroup differences). Lifestyle interventions reduced weight (mean difference [95% CI]: −3.87 kg [−5.76, −1.97], I2 = 95.03%) and fasting blood glucose (mean difference [95% CI]: −0.15 mM [−0.25, −0.04], I2 = 0%). Greater weight loss was observed for interventions with a weight loss aim (−4.19 kg [−6.30, −1.92] vs −0.81 kg [−1.48, −0.14], P = 0.003 for subgroup differences). Greater weight loss was observed for interventions delivered solely via face-to-face (−6.02 kg [−8.96, −3.07]) compared to those delivered via a combination of face-to-face and technology (−2.21 kg [−3.62, −0.81], P = 0.02 for subgroup differences). WIDER IMPLICATIONS: Effectiveness of preconception lifestyle interventions aiming to enhance fertility may be improved by a structured, intensive approach. Preconception lifestyle interventions reduce weight, particularly face-to-face interventions with a weight loss aim. However, these findings based on subgroup analyses should be interpreted with caution and warrant further investigation due to the exploratory nature of the analysis, limited number of studies included, and potential aggregation bias of study-level subgroup effects. Selection of intervention characteristics for future preconception lifestyle interventions should consider patient preferences and practical considerations. REGISTRATION: This review was prospectively registered in the Prospective Register of Systematic Reviews (PROSPERO) (CRD42022333066).
- Open Access
- 25 June 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 104 (9) , 1694-1704
Metabolic associations of human placental lactogen in pregnancies at high metabolic risk: An observational cohort study
Introduction: Human placental lactogen (hPL) is a placental hormone which, according to preclinical research, appears to have key metabolic roles in pregnancy. We aimed to examine pregnancy hPL levels in relation to maternal metabolic parameters and fetal outcomes within an ethnically diverse cohort at high metabolic risk. Design was an observational cohort study, nested within a randomized controlled trial.Material and Methods: Pregnant women (n = 130), recruited for high metabolic risk, underwent measurement of hPL, plus clinical and metabolic parameters, in early pregnancy (15.8 ± 2.5 weeks of gestation). Univariable and multivariable simple linear regression models were used to examine relationships between early pregnancy hPL and key maternal anthropometric and biochemical variables. Fifty‐four women progressed to serial measurement of hPL and metabolic parameters across pregnancy. Univariable and multivariable mixed effects regression models were used to explore relationships between hPL and maternal variables across pregnancy, with repeated measures adjusted for using random effects.Results: In early pregnancy, lower hPL levels were independently associated with higher maternal fasting glucose (β = −1.03, p < 0.01). Early pregnancy hPL was not significantly related to maternal obesity, gestational diabetes mellitus (GDM), or polycystic ovary syndrome status. In women with GDM, sampled serially across pregnancy, maternal hPL and leptin levels were inversely associated (adjusted β = −0.098, p ≤ 0.001). There was a significant relationship between higher late pregnancy hPL and increased infant birthweight in the serially sampled GDM cohort, both before (β = 50.81, p = 0.01) and after (β = 41.78, p = 0.02) adjustment for gestational age at birth.Conclusions: Maternal hPL may play a role in maternal metabolic adaptation to pregnancy, particularly in relation to glucose and leptin dynamics. hPL in late pregnancy is positively associated with infant birthweight in women with GDM. Future studies of hPL in well‐defined contemporary populations are warranted, both to understand mechanistic interactions in pregnancy and potentially as a biomarker for infant birthweight.
- 25 June 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 104 (9) , 1694-1704
Open AccessMetabolic associations of human placental lactogen in pregnancies at high metabolic risk: An observational cohort study
Introduction: Human placental lactogen (hPL) is a placental hormone which, according to preclinical research, appears to have key metabolic roles in pregnancy. We aimed to examine pregnancy hPL levels in relation to maternal metabolic parameters and fetal outcomes within an ethnically diverse cohort at high metabolic risk. Design was an observational cohort study, nested within a randomized controlled trial.Material and Methods: Pregnant women (n = 130), recruited for high metabolic risk, underwent measurement of hPL, plus clinical and metabolic parameters, in early pregnancy (15.8 ± 2.5 weeks of gestation). Univariable and multivariable simple linear regression models were used to examine relationships between early pregnancy hPL and key maternal anthropometric and biochemical variables. Fifty‐four women progressed to serial measurement of hPL and metabolic parameters across pregnancy. Univariable and multivariable mixed effects regression models were used to explore relationships between hPL and maternal variables across pregnancy, with repeated measures adjusted for using random effects.Results: In early pregnancy, lower hPL levels were independently associated with higher maternal fasting glucose (β = −1.03, p < 0.01). Early pregnancy hPL was not significantly related to maternal obesity, gestational diabetes mellitus (GDM), or polycystic ovary syndrome status. In women with GDM, sampled serially across pregnancy, maternal hPL and leptin levels were inversely associated (adjusted β = −0.098, p ≤ 0.001). There was a significant relationship between higher late pregnancy hPL and increased infant birthweight in the serially sampled GDM cohort, both before (β = 50.81, p = 0.01) and after (β = 41.78, p = 0.02) adjustment for gestational age at birth.Conclusions: Maternal hPL may play a role in maternal metabolic adaptation to pregnancy, particularly in relation to glucose and leptin dynamics. hPL in late pregnancy is positively associated with infant birthweight in women with GDM. Future studies of hPL in well‐defined contemporary populations are warranted, both to understand mechanistic interactions in pregnancy and potentially as a biomarker for infant birthweight.
- 14 May 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (10) , e1980-e1981
Response to Letter to the Editor From de Zegher and Ibáñez: “Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis”
De Zegher and Ibanez suggest that metformin should be first-line treatment with the addition of combined oral contraceptive pills (COCPs) if needed for adolescents with polycystic ovary syndrome (PCOS), as this is a more physiological option ( 1). This is not a new viewpoint, as the authors have expressed similar opinions in previous correspondence ( 2). Here we address this comment based on evidence-based medicine and the need for established efficacy, rather than isolated physiological responses, as the basis for treatment recommendations. The evidence-based International PCOS Guideline processes ( 3) generated recommendations to consider COCPs for the management of irregular cycles and hirsutism and metformin for metabolic indications in women with PCOS ( 4). To date, there is no evidence of short- or long-term overall symptomatic benefits of metformin over COCP ( 4). While metformin has a definite role in PCOS, it fails to provide contraception or endometrial protection. We also highlight that comparing ovulatory rates between metformin and COCPs is inappropriate other than when ovulation is an outcome, such as in the context of infertility or contraception. Furthermore, many women with PCOS have hyperandrogenic symptoms. Meta-analyses document that metformin is ineffective in reducing these symptoms ( 4).
- 14 May 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (10) , e1980-e1981
Response to Letter to the Editor From de Zegher and Ibáñez: “Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis”
De Zegher and Ibanez suggest that metformin should be first-line treatment with the addition of combined oral contraceptive pills (COCPs) if needed for adolescents with polycystic ovary syndrome (PCOS), as this is a more physiological option ( 1). This is not a new viewpoint, as the authors have expressed similar opinions in previous correspondence ( 2). Here we address this comment based on evidence-based medicine and the need for established efficacy, rather than isolated physiological responses, as the basis for treatment recommendations. The evidence-based International PCOS Guideline processes ( 3) generated recommendations to consider COCPs for the management of irregular cycles and hirsutism and metformin for metabolic indications in women with PCOS ( 4). To date, there is no evidence of short- or long-term overall symptomatic benefits of metformin over COCP ( 4). While metformin has a definite role in PCOS, it fails to provide contraception or endometrial protection. We also highlight that comparing ovulatory rates between metformin and COCPs is inappropriate other than when ovulation is an outcome, such as in the context of infertility or contraception. Furthermore, many women with PCOS have hyperandrogenic symptoms. Meta-analyses document that metformin is ineffective in reducing these symptoms ( 4).
- Open Access
- 17 January 2024
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 30 (3) , 243-261
Assessing the influence of preconception diet on male fertility: a systematic scoping review
The last decade has seen increased research on the relationship between diet and male fertility, but there are no clearly defined nutritional recommendations for men in the preconception period to support clinical fertility outcomes. The purpose of this scoping review is to examine the extent and range of research undertaken to evaluate the effect(s) of diet in the preconception period on male clinical fertility and reproductive outcomes. Four electronic databases (MEDLINE and EMBASE via Ovid, CAB Direct, and CINAHL via EBSCO) were searched from inception to July 2023 for randomized controlled trials (RCTs) and observational studies (prospective/retrospective, case–control, and cross-sectional). Intervention studies in male participants or couples aiming to achieve dietary or nutritional change, or non-intervention studies examining dietary or nutritional components (whole diets, dietary patterns, food groups or individual foods) in the preconception period were included. Controls were defined as any comparison group for RCTs, and any/no comparison for observational studies. Primary outcomes of interest included the effect(s) of male preconception diet on clinical outcomes such as conception (natural or via ART), pregnancy rates and live birth rates. Secondary outcomes included time to conception and sperm parameters. A total of 37 studies were eligible, including one RCT and 36 observational studies (prospective, cross-sectional, and case–control studies; four studies in non-ART populations) published between 2008 and 2023. Eight reported clinical outcomes, 26 reported on secondary outcomes, and three reported on both. The RCT did not assess clinical outcomes but found that tomato juice may benefit sperm motility. In observational studies, some evidence suggested that increasing fish or reducing sugar-sweetened beverages, processed meat or total fat may improve fecundability. Evidence for other clinical outcomes, such as pregnancy rates or live birth rates, showed no relationship with cereals, soy and dairy, and inconsistent relationships with consuming red meat or a ‘healthy diet’ pattern. For improved sperm parameters, limited evidence supported increasing fish, fats/fatty acids, carbohydrates and dairy, and reducing processed meat, while the evidence for fruits, vegetables, cereals, legumes, eggs, red meat and protein was inconsistent. Healthy diet patterns in general were shown to improve sperm health. Specific dietary recommendations for improving male fertility are precluded by the lack of reporting on clinical pregnancy outcomes, heterogeneity of the available literature and the paucity of RCTs to determine causation or to rule out reverse causation. There may be some benefit from increasing fish, adopting a healthy dietary pattern, and reducing consumption of sugar-sweetened beverages and processed meat, but it is unclear whether these benefits extend beyond sperm parameters to improve clinical fertility. More studies exploring whole diets rather than singular foods or nutritional components in the context of male fertility are encouraged, particularly by means of RCTs where feasible. Further assessment of core fertility outcomes is warranted and requires careful planning in high-quality prospective studies and RCTs. These studies can lay the groundwork for targeted dietary guidelines and enhance the prospects of successful fertility outcomes for men in the preconception period. Systematic search of preconception diet suggests that increasing fish and reducing sugary drinks, processed meats and total fat may improve male fertility, while consuming healthy diets, fish, fats/fatty acids, carbohydrates and dairy and reducing processed meat can improve sperm health. Systematic search of preconception diet suggests that increasing fish and reducing sugary drinks, processed meats and total fat may improve male fertility, while consuming healthy diets, fish, fats/fatty acids, carbohydrates and dairy and reducing processed meat can improve sperm health.
- 17 January 2024
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 30 (3) , 243-261
Open AccessAssessing the influence of preconception diet on male fertility: a systematic scoping review
The last decade has seen increased research on the relationship between diet and male fertility, but there are no clearly defined nutritional recommendations for men in the preconception period to support clinical fertility outcomes. The purpose of this scoping review is to examine the extent and range of research undertaken to evaluate the effect(s) of diet in the preconception period on male clinical fertility and reproductive outcomes. Four electronic databases (MEDLINE and EMBASE via Ovid, CAB Direct, and CINAHL via EBSCO) were searched from inception to July 2023 for randomized controlled trials (RCTs) and observational studies (prospective/retrospective, case–control, and cross-sectional). Intervention studies in male participants or couples aiming to achieve dietary or nutritional change, or non-intervention studies examining dietary or nutritional components (whole diets, dietary patterns, food groups or individual foods) in the preconception period were included. Controls were defined as any comparison group for RCTs, and any/no comparison for observational studies. Primary outcomes of interest included the effect(s) of male preconception diet on clinical outcomes such as conception (natural or via ART), pregnancy rates and live birth rates. Secondary outcomes included time to conception and sperm parameters. A total of 37 studies were eligible, including one RCT and 36 observational studies (prospective, cross-sectional, and case–control studies; four studies in non-ART populations) published between 2008 and 2023. Eight reported clinical outcomes, 26 reported on secondary outcomes, and three reported on both. The RCT did not assess clinical outcomes but found that tomato juice may benefit sperm motility. In observational studies, some evidence suggested that increasing fish or reducing sugar-sweetened beverages, processed meat or total fat may improve fecundability. Evidence for other clinical outcomes, such as pregnancy rates or live birth rates, showed no relationship with cereals, soy and dairy, and inconsistent relationships with consuming red meat or a ‘healthy diet’ pattern. For improved sperm parameters, limited evidence supported increasing fish, fats/fatty acids, carbohydrates and dairy, and reducing processed meat, while the evidence for fruits, vegetables, cereals, legumes, eggs, red meat and protein was inconsistent. Healthy diet patterns in general were shown to improve sperm health. Specific dietary recommendations for improving male fertility are precluded by the lack of reporting on clinical pregnancy outcomes, heterogeneity of the available literature and the paucity of RCTs to determine causation or to rule out reverse causation. There may be some benefit from increasing fish, adopting a healthy dietary pattern, and reducing consumption of sugar-sweetened beverages and processed meat, but it is unclear whether these benefits extend beyond sperm parameters to improve clinical fertility. More studies exploring whole diets rather than singular foods or nutritional components in the context of male fertility are encouraged, particularly by means of RCTs where feasible. Further assessment of core fertility outcomes is warranted and requires careful planning in high-quality prospective studies and RCTs. These studies can lay the groundwork for targeted dietary guidelines and enhance the prospects of successful fertility outcomes for men in the preconception period. Systematic search of preconception diet suggests that increasing fish and reducing sugary drinks, processed meats and total fat may improve male fertility, while consuming healthy diets, fish, fats/fatty acids, carbohydrates and dairy and reducing processed meat can improve sperm health. Systematic search of preconception diet suggests that increasing fish and reducing sugary drinks, processed meats and total fat may improve male fertility, while consuming healthy diets, fish, fats/fatty acids, carbohydrates and dairy and reducing processed meat can improve sperm health.
- Top Cited PapersOpen Access
- 9 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , e817-e836
Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis
Context: Polycystic ovary syndrome (PCOS) affects more than 1 in 10 women. Objective: As part of the 2023 International PCOS Guidelines update, comparisons between combined oral contraceptive pills (COCP), metformin, and combination treatment were evaluated. Data Sources: Ovid Medline, Embase, PsycINFO, All EBM, and CINAHL were searched. Study Selection: Women with PCOS included in randomized controlled trials (RCTs). Data Extraction: We calculated mean differences and 95% CIs regarding anthropometrics, metabolic, and hyperandrogenic outcomes. Meta-analyses and quality assessment using GRADE were performed. Data Synthesis: The search identified 1660 publications; 36 RCTs were included. For hirsutism, no differences were seen when comparing metformin vs COCP, nor when comparing COCP vs combination treatment with metformin and COCP. Metformin was inferior on free androgen index (FAI) (7.08; 95% CI 4.81, 9.36), sex hormone binding globulin (SHBG) (−118.61 nmol/L; 95% CI −174.46, −62.75) and testosterone (0.48 nmol/L; 95% CI 0.32, 0.64) compared with COCP. COCP was inferior for FAI (0.58; 95% CI 0.36, 0.80) and SHBG (−16.61 nmol/L; 95% CI −28.51, −4.71) compared with combination treatment, whereas testosterone did not differ. Metformin lowered insulin (−27.12 pmol/L; 95% CI −40.65, −13.59) and triglycerides (−0.15 mmol/L; 95% CI −0.29, −0.01) compared with COCP. COCP was inferior for insulin (17.03 pmol/L; 95% CI 7.79, 26.26) and insulin resistance (0.44; 95% CI 0.17, 0.70) compared with combination treatment. Conclusions: The choice of metformin or COCP treatment should be based on symptoms, noting some biochemical benefits from combination treatment targeting both major endocrine disturbances seen in PCOS (hyperinsulinemia and hyperandrogenism).
- 9 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , e817-e836
Top Cited PapersOpen AccessMetformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis
Context: Polycystic ovary syndrome (PCOS) affects more than 1 in 10 women. Objective: As part of the 2023 International PCOS Guidelines update, comparisons between combined oral contraceptive pills (COCP), metformin, and combination treatment were evaluated. Data Sources: Ovid Medline, Embase, PsycINFO, All EBM, and CINAHL were searched. Study Selection: Women with PCOS included in randomized controlled trials (RCTs). Data Extraction: We calculated mean differences and 95% CIs regarding anthropometrics, metabolic, and hyperandrogenic outcomes. Meta-analyses and quality assessment using GRADE were performed. Data Synthesis: The search identified 1660 publications; 36 RCTs were included. For hirsutism, no differences were seen when comparing metformin vs COCP, nor when comparing COCP vs combination treatment with metformin and COCP. Metformin was inferior on free androgen index (FAI) (7.08; 95% CI 4.81, 9.36), sex hormone binding globulin (SHBG) (−118.61 nmol/L; 95% CI −174.46, −62.75) and testosterone (0.48 nmol/L; 95% CI 0.32, 0.64) compared with COCP. COCP was inferior for FAI (0.58; 95% CI 0.36, 0.80) and SHBG (−16.61 nmol/L; 95% CI −28.51, −4.71) compared with combination treatment, whereas testosterone did not differ. Metformin lowered insulin (−27.12 pmol/L; 95% CI −40.65, −13.59) and triglycerides (−0.15 mmol/L; 95% CI −0.29, −0.01) compared with COCP. COCP was inferior for insulin (17.03 pmol/L; 95% CI 7.79, 26.26) and insulin resistance (0.44; 95% CI 0.17, 0.70) compared with combination treatment. Conclusions: The choice of metformin or COCP treatment should be based on symptoms, noting some biochemical benefits from combination treatment targeting both major endocrine disturbances seen in PCOS (hyperinsulinemia and hyperandrogenism).
- Top Cited PapersOpen Access
- 2 August 2023
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 189 (2) , S38-S64
The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Objective: Available evidence has shown that metformin improves insulin sensitivity and weight management in polycystic ovary syndrome (PCOS). Nevertheless, key knowledge gaps remain regarding its efficacy and the specific outcomes in this population. This review evaluates the effectiveness of metformin and lifestyle modification compared with placebo in the management of PCOS and will inform the forthcoming, 2023 evidence-based PCOS guidelines. Design: Systematic review and meta-analysis of the literature. Methods: A search was performed in MEDLINE, EMBASE, PsycINFO, All EBM, and CINAHL. The review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and included randomized controlled trials published in English through July 2022. Results: Moderate certainty of evidence showed a larger reduction of body mass index (BMI) (mean difference [MD] −0.53, 95% confidence interval [CI] −0.95 to −0.12 kg/m2), homeostatic model assessment for insulin resistance (MD −0.50, 95% CI −0.91 to −0.09) (critical outcomes), and fasting glucose (MD −0.13, 95% CI −0.19 to −0.07 mmol/L) with metformin compared to placebo with increased mild gastrointestinal adverse effects (odds ratio [OR] 7.67, 95% CI 2.74–21.46). Low certainty of evidence showed a larger reduction of waist–hip ratio (MD −0.02, 95% CI −0.03 to −0.00), total cholesterol (MD −0.24, 95% CI −0.43 to −0.05 mmol/L), low-density lipoprotein (MD −0.16, 95% CI −0.30 to −0.01 mmol/L), and triglycerides (MD −0.11, 95% CI −0.20 to −0.02 mmol/L) with metformin than placebo. Conclusions: Metformin should be considered an efficacious adjunct to lifestyle interventions in adults with PCOS, especially for those with a higher BMI, to improve weight loss, insulin resistance, and lipids.
- 2 August 2023
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 189 (2) , S38-S64
Top Cited PapersOpen AccessThe impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Objective: Available evidence has shown that metformin improves insulin sensitivity and weight management in polycystic ovary syndrome (PCOS). Nevertheless, key knowledge gaps remain regarding its efficacy and the specific outcomes in this population. This review evaluates the effectiveness of metformin and lifestyle modification compared with placebo in the management of PCOS and will inform the forthcoming, 2023 evidence-based PCOS guidelines. Design: Systematic review and meta-analysis of the literature. Methods: A search was performed in MEDLINE, EMBASE, PsycINFO, All EBM, and CINAHL. The review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and included randomized controlled trials published in English through July 2022. Results: Moderate certainty of evidence showed a larger reduction of body mass index (BMI) (mean difference [MD] −0.53, 95% confidence interval [CI] −0.95 to −0.12 kg/m2), homeostatic model assessment for insulin resistance (MD −0.50, 95% CI −0.91 to −0.09) (critical outcomes), and fasting glucose (MD −0.13, 95% CI −0.19 to −0.07 mmol/L) with metformin compared to placebo with increased mild gastrointestinal adverse effects (odds ratio [OR] 7.67, 95% CI 2.74–21.46). Low certainty of evidence showed a larger reduction of waist–hip ratio (MD −0.02, 95% CI −0.03 to −0.00), total cholesterol (MD −0.24, 95% CI −0.43 to −0.05 mmol/L), low-density lipoprotein (MD −0.16, 95% CI −0.30 to −0.01 mmol/L), and triglycerides (MD −0.11, 95% CI −0.20 to −0.02 mmol/L) with metformin than placebo. Conclusions: Metformin should be considered an efficacious adjunct to lifestyle interventions in adults with PCOS, especially for those with a higher BMI, to improve weight loss, insulin resistance, and lipids.
- Open Access
- 19 July 2023
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 29 (6) , 811-828
Assessing the influence of preconception diet on female fertility: a systematic scoping review of observational studies
BACKGROUND: Preconception diet is a proposed modifiable risk factor for infertility. However, there is no official guidance for women in the preconception period as to which dietary approaches may improve fertility. OBJECTIVE AND RATIONALE: A comprehensive synthesis of the relevant evidence is key to determine the potentially effective dietary patterns and components as well as evidence gaps, and to provide information for nutritional recommendations for couples planning a pregnancy. SEARCH METHODS: In this systematic scoping review, four electronic databases (Medline and EMBASE via Ovid processing, CAB Direct, and CINAHL via EBSCO) were searched for observational studies (prospective and retrospective cohort, cross-sectional, and case–control studies) from inception to 27 September 2021. Eligible studies included women of reproductive age during the preconception period, and evaluated exposures related to preconception diet and outcomes related to fertility. Results were synthesized using a descriptive approach. OUTCOMES: A total of 36 studies were eligible for inclusion (31 prospective, 3 cross-sectional, and 2 case–control studies) and were published between 2007 and 2022. Of the assessed dietary exposures, increased adherence to the Mediterranean diet displayed the strongest and most consistent association with improved clinical pregnancy rates. Reducing trans fatty acids (TFAs), saturated fatty acids, and discretionary food intake (fast food and sugar-sweetened beverages) were associated with improvements in live birth, clinical pregnancy rates, and related ART outcomes. The dietary components of seafood, dairy, and soy demonstrated inconsistent findings across the few included studies. WIDER IMPLICATIONS: Due to heterogeneity and the limited available literature on most exposures, there is insufficient evidence to support any specific dietary approach for improving fertility. However, following some of the dietary approaches outlined in this review (anti-inflammatory diets, reducing TFA, and discretionary food intake) are consistent with broad healthy eating guidelines, have little to no associated risk, and offer a plausible set of possible benefits. This warrants further exploration in randomized controlled trials.
- 19 July 2023
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 29 (6) , 811-828
Open AccessAssessing the influence of preconception diet on female fertility: a systematic scoping review of observational studies
BACKGROUND: Preconception diet is a proposed modifiable risk factor for infertility. However, there is no official guidance for women in the preconception period as to which dietary approaches may improve fertility. OBJECTIVE AND RATIONALE: A comprehensive synthesis of the relevant evidence is key to determine the potentially effective dietary patterns and components as well as evidence gaps, and to provide information for nutritional recommendations for couples planning a pregnancy. SEARCH METHODS: In this systematic scoping review, four electronic databases (Medline and EMBASE via Ovid processing, CAB Direct, and CINAHL via EBSCO) were searched for observational studies (prospective and retrospective cohort, cross-sectional, and case–control studies) from inception to 27 September 2021. Eligible studies included women of reproductive age during the preconception period, and evaluated exposures related to preconception diet and outcomes related to fertility. Results were synthesized using a descriptive approach. OUTCOMES: A total of 36 studies were eligible for inclusion (31 prospective, 3 cross-sectional, and 2 case–control studies) and were published between 2007 and 2022. Of the assessed dietary exposures, increased adherence to the Mediterranean diet displayed the strongest and most consistent association with improved clinical pregnancy rates. Reducing trans fatty acids (TFAs), saturated fatty acids, and discretionary food intake (fast food and sugar-sweetened beverages) were associated with improvements in live birth, clinical pregnancy rates, and related ART outcomes. The dietary components of seafood, dairy, and soy demonstrated inconsistent findings across the few included studies. WIDER IMPLICATIONS: Due to heterogeneity and the limited available literature on most exposures, there is insufficient evidence to support any specific dietary approach for improving fertility. However, following some of the dietary approaches outlined in this review (anti-inflammatory diets, reducing TFA, and discretionary food intake) are consistent with broad healthy eating guidelines, have little to no associated risk, and offer a plausible set of possible benefits. This warrants further exploration in randomized controlled trials.